{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-039412","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.213137+00:00","generated_at":"2026-06-11T10:04:25.634951+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Galectin Q2 net loss $9.2M; NAVIGATE trial interim analysis expected Q4 2024","bullets":["Net loss per share $0.15 for Q2 2023 vs $0.16 in Q2 2022; R&D expenses $7.4M down from $8.1M.","Cash and equivalents $18.0M as of June 30, 2023; additional $30M available under chairman's credit line.","NAVIGATE trial (NASH cirrhosis) fully randomized with 357 patients; Phase 2b interim analysis expected Q4 2024.","Company evaluating Phase 2 trial of belapectin plus Keytruda in advanced head and neck cancers.","Belapectin safety profile remains encouraging; no approved therapy for NASH cirrhosis with portal hypertension."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-039412","json":"https://secwatch.observer/filing/0001140361-23-039412.json","markdown":"https://secwatch.observer/filing/0001140361-23-039412.md","text":"https://secwatch.observer/filing/0001140361-23-039412.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123039412/0001140361-23-039412-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123039412/brhc20057380_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:04:25.634951+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"317b719ab04f474e440c0f6cfd0cff47d3eb7399","claim":"GALECTIN THERAPEUTICS INC reported the three months ended June 30, 2023 results: net income a net loss applicable to common stockholders of $9.2 million, or ($0.15) per share, EPS ($0.15) per share.","evidence_excerpt":"For the three months ended June 30, 2023, the Company reported a net loss applicable to common stockholders of $9.2 million, or ($0.15) per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123039412/0001140361-23-039412-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended June 30, 2023"},{"label":"Net income","value":"a net loss applicable to common stockholders of $9.2 million, or ($0.15) per share"},{"label":"EPS","value":"($0.15) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"eff444e7f5f7e1ebd83c7ac7799693a5d9c93027","claim":"GALECTIN THERAPEUTICS INC reported financial results for the six months ended June 30, 2023.","evidence_excerpt":"announcing its results of operations and financial condition as of and for the three and six months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123039412/0001140361-23-039412-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}